Bristol-Myers announced it would permanently end clinical trials of its hepatitis C drug after a study participant died of heart failure, according to a Bloomberg Businessweek report.
Earlier this months, the company suspended clinical trials of the drug BMS-986094, citing "the emergence of a serious safety issue." Until now, officials have stayed mum on the exact risk posed to patients.
In addition to the participant who died, eight others were hospitalized due to adverse reactions to the drug. Bristol-Myers is investigating what caused the hospitalizations, though heart and kidney toxicity could be a factor.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Earlier this months, the company suspended clinical trials of the drug BMS-986094, citing "the emergence of a serious safety issue." Until now, officials have stayed mum on the exact risk posed to patients.
In addition to the participant who died, eight others were hospitalized due to adverse reactions to the drug. Bristol-Myers is investigating what caused the hospitalizations, though heart and kidney toxicity could be a factor.
More Articles on Patient Safety:
Kansas Healthcare Providers Partner for Infection Prevention Education
Loyola University Receives Grant for Infection Prevention Education
